This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Northwest Bio Can't Keep Its DC-Vax Claims Straight

08/14/14 - 10:20 AM EDT

Contradictory statements made on whether or not Northwest Bio conducted an interim analysis of its DC-Vax phase III study.

READ FULL POST

Blame MannKind's Fall on its Bloated Balance Sheet

08/13/14 - 12:04 PM EDT

Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.

READ FULL POST

Arrowhead Discloses First Human Hepatitis B Therapy Results

08/12/14 - 05:11 PM EDT

The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.

READ FULL POST

Dendreon Warns Debt Bomb Might Wipe Out Shareholders

08/12/14 - 07:17 AM EDT

The struggling Provenge peddler is suffocating under $620 million in debt and the bill comes soon.

READ FULL POST

Intercept Pharma Shares Higher on Positive Fatty Liver Drug Data

08/11/14 - 05:29 PM EDT

Intercept's OCA data look good. I don't see anything in the study results which scream, "RUN AWAY!" This is what some investors feared, causing the stock price to fall recently.

READ FULL POST

Sarepta Should Shut Up About Ebola, Focus on Job No. 1

08/06/14 - 12:07 PM EDT

By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.

READ FULL POST

The Tekmira Ebola Trade May Already Be Over

08/04/14 - 10:07 AM EDT

CNN reports competing, secret Ebola therapy already saved lives of U.S. aid workers.

READ FULL POST

Cel-Sci's Enrollment Math Doesn't Add up

08/01/14 - 11:11 AM EDT

In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.

READ FULL POST

Galectin Drug is a Fatty Liver Flop

07/29/14 - 10:26 AM EDT

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

READ FULL POST

Galectin Pays Stock Promoters to Entice Retail Investors

07/28/14 - 12:34 PM EDT

Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.

READ FULL POST

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs